Increasing research is exploring the combination of PD-1/PD-L1 inhibitors with other therapies, such as anti-VEGF agents, tumor vaccines, or metabolic interventions, to overcome the immunosuppressive TME and enhance the effectiveness of immunotherapy (3, 24, 39). This evidence concerns the gene CD274 and neoplasm.